HRT for Perimenopause: Types, Evidence, and Common Concerns

DEFINITION

HRT (Hormone Replacement Therapy)

Treatment that replaces declining estrogen (and progesterone, for women with a uterus) to reduce perimenopause and menopause symptoms. Available in systemic forms (absorbed into the bloodstream — patches, gels, sprays, pills) and local forms (topical estrogen for vaginal/urinary symptoms only).

DEFINITION

Progestogen

The progesterone component added to HRT for women with a uterus, to protect against endometrial hyperplasia (thickening of the uterine lining) that estrogen alone would cause. Micronized progesterone (body-identical) has a more favorable safety profile than older synthetic progestogens.

What HRT Does

HRT replaces the hormones — primarily estrogen, and progesterone for women with a uterus — that decline during perimenopause. By stabilizing hormone levels, it reduces or eliminates the symptoms driven by that decline.

The evidence base is strongest for vasomotor symptoms (hot flashes and night sweats), where clinical trials show 75-90% reductions in frequency. Sleep, mood, cognitive function, and genitourinary symptoms also show significant improvement with HRT in clinical trial data.

What Changed After 2002

The 2002 Women’s Health Initiative (WHI) study raised concerns about breast cancer and cardiovascular risk that led to a significant drop in HRT prescribing. Subsequent analysis revealed major limitations: the study used older oral combined HRT formulations (not transdermal estrogen), in women whose average age was 63 — a decade or more past menopause for most. Applying those findings to perimenopausal women in their 40s was methodologically inappropriate.

Current clinical guidelines from the Menopause Society, the British Menopause Society, and the European Menopause and Andropause Society reflect updated evidence and support HRT for most healthy women under 60 or within 10 years of menopause.

Types of HRT

Estrogen delivery: Transdermal forms (patches, gels, sprays) bypass liver metabolism and are associated with lower clotting risk than oral tablets. Most current clinical guidance favors transdermal routes for most women.

Progestogen choice: Micronized progesterone (e.g., Utrogestan) is body-identical and has a more favorable risk profile than older synthetic progestogens, including a lower associated breast cancer risk in some analyses.

Local vaginal estrogen: Applied directly to vaginal tissue, it addresses genitourinary symptoms (dryness, urinary urgency, recurrent infections) with minimal systemic absorption. It is safe indefinitely and does not require progestogen.

Starting the Conversation

A doctor or menopause specialist can assess whether HRT is appropriate based on your symptom pattern, health history, and risk factors. Bringing a symptom log that covers several weeks is more useful than trying to describe symptoms verbally.